Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Multiple Olomorasib Capsules
NCT07044271Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2025
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of olomorasib in solid tumor (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration versus Time Curve from Time Zero to Time t at 72 hours, Area Under the Concentration versus Time Curve from Zero to Infinity at 72 hours and 1 more. Started Jul 2025; status: completed.
02
Drugs
olomorasib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07044271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07044271.